Sensitivity for MRD detection is important for all types of cancer and is particularly critica for cancers that shed relatively small amounts of circulating tumor DNA (ctDNA) into the bloodstream such as lung and breast cancer. Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse. There are typical start up pains that are to be expected and right now the company is currently going through a lot of changes. "PhasED-Seq has been used in more than 20 different clinical studies, and can predict cancer relapse when tumor burden is low and patients are more likely to favorably respond to anti-tumor therapy. Overall Foresight has been a great place to work.
"Ultra-sensitive MRD tests are essential to detect residual disease and recurrence following completion of curative intent therapies," said Dr Ash Alizadeh, MD/PhD, co-founder and Chief Medical Advisor at Foresight. The test offers unprecedented sensitivity for MRD detection, enabling a limit of detection below one part per million. Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse. The test is custom designed for each patient to track phased variants identified from tumor tissue samples using whole genome sequencing. This granted patent covers Foresight's PhasED-Seq technology and the workflow behind the Foresight Solid Tumor Recurrence Test, an assay used to detect minimum residual disease (MRD) from the plasma of cancer patients using DNA sequencing.
0 kommentar(er)
